Montelukast +pharma

Montelukast, the active ingredient in Montelukast +pharma, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory and allergic conditions.

Asthma: reduces frequency and severity of bronchospasm as maintenance therapy. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema or severe allergic reaction - Mood changes, including depression - Suicidal thoughts or behavior

Before prescribing Montelukast, consider the following safety measures.

Assess hepatic function: monitor liver enzymes in patients with liver disease. Monitor for neuropsychiatric events: watch for mood changes or suicidal ideation. Use with caution in severe asthma: not a rescue medication. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep in original pack, protect from moisture.

Montelukast can interact with several medicines; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Montelukast levels. - Phenobarbital: may lower drug concentration. - Rifampin: can reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of rash. - Antidepressants: may exacerbate neuropsychiatric side effects.